ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "IL-6"

  • Abstract Number: 1426 • 2015 ACR/ARHP Annual Meeting

    The Effect of Anti-Interleukin-6 Receptor Antibody in Ovariectomized Mice

    Sho Kato1, Hiroki Wakabayashi2, Taro Nakagawa3, Yohei Naito3, Takahiro Iino4 and Akihiro Sudo5, 1Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan, 2Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan, 3Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, 4Mie University Graduate School of Medicine, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, 5Orthopaedic surgery, Mie University Postgraduate School of Medicine, Tsu-city, Japan

    Background/Purpose: Osteoporotic patients with no evidence of fractures sometimes experience vague low back pain. Bone pain associated with bone metastasis may also be related to…
  • Abstract Number: 1530 • 2015 ACR/ARHP Annual Meeting

    Neutrophil Function and Survival Unaffected in Healthy Subjects Following Single Administration of Tocilizumab

    Laurence Lok1, Jatinder Juss1, Neda Farahi1, Chrystalla Loutsios1, Chandra Solanki2, Adrien Michael Peters3, Sophie Dimonaco4, Francis Donaldson4, Benjamin Porter-Brown4 and Edwin Chilvers1, 1Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, 2Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge, United Kingdom, 3Division of Clinical and Laboratory Investigation, Brighton and Sussex Medical School, Brighton, United Kingdom, 4Roche Products Ltd., Welwyn Garden City, United Kingdom

    Background/Purpose: Decreases in circulating neutrophil counts have been observed in adults with rheumatoid arthritis (RA) and children with systemic or polyarticular juvenile idiopathic arthritis treated…
  • Abstract Number: 1635 • 2015 ACR/ARHP Annual Meeting

    Development of New Bioassay System Measuring Inhibitory Strength of IL-6/STAT3 Signal Under Tocilizumab Treatment in Rheumatoid Arthritis Patients

    Shuntaro Saito1, Katsuya Suzuki1, Kunihiro Yamaoka1 and Tsutomu Takeuchi2, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Tocilizumab (TCZ) is a IL-6 receptor blockade, administered intravenously every 4 weeks and efficiently inhibits IL-6/STAT3 signaling pathway. We have previously reported the usefulness…
  • Abstract Number: 1682 • 2015 ACR/ARHP Annual Meeting

    Suppression of Chronic Arthritis By a Novel Nuclear Factor of Activated T-Cell 5 (NFAT5) Inhibitor

    Wan-Uk Kim1, Eun-Jin Han2, Chong-Hyeon Yoon3, Ki-Jo Kim4, Seung-Ah Yoo5, Bong Ki Hong5 and Saseong Lee5, 1Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, 2Institute of Bone & Joint Disease, The Catholic University of Korea, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 4St. Mary's Hospital, Seoul, South Korea, 5Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea

    Background/Purpose: We reported that nuclear factor of activated T-cells 5 (NFAT5), originally identified as an osmo-protective transcription factor, has a critical role in the pathogenesis…
  • Abstract Number: 1786 • 2015 ACR/ARHP Annual Meeting

    Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE

    Vibeke Strand1, Annette Diehl2, Jared Christensen2, Joseph Wajdula2, Sudhakar Sridharan3 and Paul J Healey2, 1Biopharmaceutical Consultant, Portola Valley, CA, 2Pfizer Inc, New York City, NY, 3PPD Inc, Rockville, MA

    Background/Purpose: The 10 mg dose of PF-04236921 showed evidence of efficacy in a phase 2 randomized controlled trial (RCT) in SLE.1,2 Here patient-reported outcomes (PROs)…
  • Abstract Number: 2905 • 2014 ACR/ARHP Annual Meeting

    The IL-6/Th17 Axis Promotes Autoantibody-Associated Autoimmune Valvular Carditis in Mice

    Jennifer L. Auger1, Brianna J. Engelson2, Yaya Wang3, Erik J. Peterson4 and Bryce A. Binstadt5, 1Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, 2Pediatrics, University of Minnesota, Minneapolis, MN, 3Medicine, University of Minnesota, Minneapolis, MN, 4University of Minnesota, Minneapolis, MN, 5Pediatric Rheumatology, University of Minnesota, Minneapolis, MN

    Background/Purpose: Autoimmune valvular carditis occurs in patients with systemic lupus erythematosus, rheumatoid arthritis and rheumatic fever, but the pathogenic mechanisms remain incompletely defined. Spontaneous autoimmune…
  • Abstract Number: 1014 • 2014 ACR/ARHP Annual Meeting

    Harpagide, a Low Molecular Weight Natural Product, Suppresses IL-1â-Induced IL-6 Expression By Blocking the Activation of p38 MAPK and Transcription Factors CEBPâ and AP-1 in Primary Human Osteoarthritis Chondrocytes

    Abdul Haseeb1 and Tariq Haqqi2, 1Anatomy and Neurobiology, Northeast Ohio Medical University (NEOMED), Rootstown, OH, 2Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH

    Background/Purpose: There is growing evidence that shows the involvement of IL-6 in cartilage degradation during OA. Significant correlation between IL-6 levels in serum as well…
  • Abstract Number: 2877 • 2014 ACR/ARHP Annual Meeting

    Novel Function of Tocilizumab As a Modulator of Interleukin-27-Mediated Anti-Inflammatory Responses

    Misato Hashizume1, Jun Kikuchi2, Keiko Yoshimoto2 and Tsutomu Takeuchi2, 1Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose The immunological roles of interleukin 27 (IL-27) have been reported in the function of regulatory T cells (Treg), monocytes and osteoclasts, and these cells…
  • Abstract Number: 952 • 2014 ACR/ARHP Annual Meeting

    A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Evaluate the Efficacy and Safety of Clazakizumab, an Anti-IL-6 Monoclonal Antibody, in Adults with Active Psoriatic Arthritis

    Philip J. Mease1, A B Gottlieb2, A Berman3, E Drescher4, J Xing5, S Banerjee5 and R Wong5, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Tufts Medical Center and Tufts University School of Medicine, Boston, MA, 3Centro Médico Privado de Reumatología, Tucuman, Argentina, 4Csolnoky Ferenc Hospital, Veszprém, Hungary, 5Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: New treatment options for psoriatic arthritis (PsA) are needed and interleukin-6 (IL-6), a cytokine with a central role in chronic inflammation, is a potential…
  • Abstract Number: 2823 • 2014 ACR/ARHP Annual Meeting

    Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naïve  Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study

    Roy Fleischmann1,2, Dennis L. Decktor3, Chunpeng Fan4, Hubert Van Hoogstraten5 and Mark C Genovese6, 1Metroplax Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2University of Texas Southwestern Medical Center, Dallas, TX, 3Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4Biostatistics, Sanofi, Bridgewater, NJ, 5Sanofi, Bridgewater, NJ, 6Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA

    Background/Purpose For patients with prior exposure to tumor necrosis factor-α inhibitor (TNF-I), the likelihood of response to subsequent treatment with a TNF-I declines with the…
  • Abstract Number: 784 • 2014 ACR/ARHP Annual Meeting

    Novel Inhibitory Effects of Mast Cells in Aortitis Involves Aortic Expression of Suppressor of Cytokine Signaling-1

    Jason Springer1, Vineesh Raveendran2, Donald Smith3, Mehrdad Maz4 and Kottarappat Dileepan2, 1Department of Rheumatology, University of Kansas Medical Center, Kansas City, KS, 2Department of Medicine, University of Kansas Medical Center, Kansas City, KS, 3University of Kansas Medical Center, Kansas City, KS, 4Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS

    Background/Purpose Early in the pathogenesis of Giant Cell Arteritis (GCA) dendritic cells interact with T cells of both Th1 and Th17 origin.  IL-6; released by…
  • Abstract Number: 2824 • 2014 ACR/ARHP Annual Meeting

    A Profile of the Efficacy of Sarilumab Plus Methotrexate in Rheumatoid Arthritis Patients: Results of a 52-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study

    Arthur Kavanaugh1, Dennis L. Decktor2, Chunpeng Fan3, Janet van Adelsberg2, Renata Martincova4 and Mark C. Genovese5, 1University of California San Diego, La Jolla, CA, 2Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3Biostatistics, Sanofi, Bridgewater, NJ, 4Sanofi Czech Republic, Prague, Czech Republic, 5Stanford University Medical Center, Palo Alto, CA

    Background/Purpose Interleukin-6 (IL-6) regulates a diverse array of activities that may underlie systemic and local symptoms of rheumatoid arthritis (RA). The efficacy of sarilumab, a…
  • Abstract Number: 497 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs

    Thomas Dörner1, Hans-Peter Tony2, Gerd Burmester1, Hendrik Schulze-Koops3, Jörg Kaufmann4, Peter Kästner5, Herbert Kellner6, Reiner Kurthen7, Sylke Wagner8, Marvin A. Peters9 and Christoph Iking-Konert10, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2University Clinic Wuerzburg, Wuerzburg, Germany, 3University Clinic Munich, Munich, Germany, 4Rheumatology Practice, Ludwigsfelde, Germany, 5MVZ Out-patient Rheumatogy Unit Erfurt, Erfurt, Germany, 6Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, 7Rheumatology Practice, Aachen, Germany, 8Practice for Internal Medicine specialized in Rheumatology, Halle, Germany, 9Roche Pharma AG, Grenzach-Wyhlen, Germany, 10University Clinic Hamburg-Eppendorf, Hamburg, Germany

    Background/Purpose: The MIRAI study evaluated a sequential exposure to 2 defined biologics under rigorous study conditions within a homogeneous population of biological naïve patients (pts)…
  • Abstract Number: 2795 • 2014 ACR/ARHP Annual Meeting

    Blockade of IL-6R Signaling by Sarilumab Suppressed Circulating Markers of Bone Resorption and Synovial Damage in Rheumatoid Arthritis Patients from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study

    Anita Boyapati1, Jérôme Msihid2, Emmanuelle Cousin3, Ling Cai4, Janet van Adelsberg1, Jennifer D Hamilton1, Neil Graham5, Tanya Momtahen6 and Stefano Fiore7, 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 2Sanofi R&D, France, Chilly-Mazarin, NJ, France, 3Sanofi R&D, France, Chilly-Mazarin, France, 4Sanofi R&D, China, Beijing, China, 5Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 6Sanofi, Bridgewater, NJ, 7Distinct Project Unit, Sanofi, Bridgewater, NJ

    Background/Purpose Rheumatoid arthritis (RA) patients develop bone and joint damage due to chronic inflammation mediated by critical cytokines, eg, IL-6. Pre-clinical studies have implicated IL-6…
  • Abstract Number: 332 • 2014 ACR/ARHP Annual Meeting

    Improvement of the Stability of RNA Aptamers Against Interleukin-17A

    Natsuki Otaki1, Asako Sasaki1, Shinsuke Hiramoto1, Masakazu Nagamine1, Shigeyuki Mori1, Tomoyoshi Kayo1, Kuniyoshi Hota1, Masayuki Takahashi1, Kazuhiko Haruta2 and Yoshikazu Nakamura3,4, 1Zenyaku Kogyo Co., Ltd., Tokyo, Japan, 22-33-7 Oizumi, Nerima, Zenyaku Kogyo Co., Ltd., Tokyo, Japan, 3Division of RNA Medical Science, The Institute of Medical Science, The University Of Tokyo, Tokyo, Japan, 4RIBOMIC Inc., Tokyo, Japan

    Background/Purpose Aptamers are RNA or DNA oligonucleotides selected for their capacity to specifically bind and inhibit the function of a target protein.  The effect is…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology